

Time: 3 Hrs

Marks: 80

Q. 1 Attempt all multiple-choice questions (MCQ)

20M

| Sr No | Questions  |   | Options  |
|-------|--|---|--|
| 1     | Reported Information on a causal relationship between an Adverse Event and a Drug is known as:                                 | a | Signal   |
|       |  | b | Benefit-Risk Analysis Database   |
|       |  | c | Individual Case Safety Report  |
|       |  | d | Post Marketing Surveillance  |
| 2     | The informed consent in a clinical trial is.....   | a | Signed document of the recruited patient for the clinical trial procedures |
|       |  | b | The subjects do not know which study treatment they receive                |
|       |  | c | Patients injected with placebo and active doses                            |
|       |  | d | Fake treatment   |
| 3     | Uppsala Monitoring Centre is located in.....   | a | India  |
|       |  | b | United Kingdom   |
|       |  | c | Sweden   |
|       |  | d | China  |
| 4     | .....is the Active Surveillance type of Pharmacovigilance method.  | a | Sentinel sites   |
|       |  | b | Spontaneous reports  |
|       |  | c | Stimulated reports   |
|       |  | d | case series  |
| 5     | A compilation of the clinical and nonclinical data on the investigational products related to the clinical study is called as: | a | Informed Consent Form  |
|       |  | b | Drug Dossier   |
|       |  | c | Protocol Amendment   |
|       |  | d | Investigator's Brochure  |

|    |  |   |  |
|----|--|---|--|
| 6  | The structure and content of Clinical Study Reports are described in.....of Schedule Y 2014. | a | Appendix VII   |
|    |  | b | Appendix IV  |
|    |  | c | Appendix II  |
|    |  | d | Annexure III   |
| 7  | Aims of Spontaneous Reporting of Adverse Drug Reactions are:                                 | a | Benefit Risk Analysis  |
|    |  | b | Reduce Cost of Drug Therapy  |
|    |  | c | Study of Drug Development  |
|    |  | d | Audit of Clinical Trials   |
| 8  | Uppsala Monitoring Center holds and maintains one of the following ICSR Database             | a | Argus Safety Database  |
|    |  | b | Materiovigilance Database  |
|    |  | c | Vigibase TM  |
|    |  | d | Toxnet   |
| 9  | Pharmaco-economics is related to:  | a | Quantitative Evaluation of Drug Effects  |
|    |  | b | Description and Analysis of cost of Drug Therapy                                   |
|    |  | c | Benefit-Risk Analysis  |
|    |  | d | Drug Utilization Study in specific Population                                      |
| 10 | ICH Guideline entitled Pharmacovigilance Planning:   | a | E 2 B  |
|    |  | b | E 19   |
|    |  | c | E 2 C  |
|    |  | d | E 2 E  |
| 11 | Which of the following is a type of Comparative Studies?                                     | a | Cohort studies   |
|    |  | b | Randomized trials  |
|    |  | c | Qualitative studies  |
|    |  | d | Test controlled studies  |
| 12 | Which of the following can be called as Phase Zero Clinical Trial?                           | a | Pre-clinical Drug Development  |
|    |  | b | Trials using Human tissue collected from patients but not conducted in the patient |
|    |  | c | Post Marketing Surveillance  |

|    |  |   |   |
|----|--|---|---|
|    |  | d | First-in-man Study to determine Pharmacokinetics of New Drug by giving a low sub therapeutic dose |
| 13 | Center for Pharmacovigilance Program of India is located at:                       | a | IPC, Ghaziabad  |
|    |  | b | CDSCO, New Delhi  |
|    |  | c | AIIMS, New Delhi  |
|    |  | d | CDL, Kolkata  |
| 14 | ICSR Management System created and maintained by the Uppsala Monitoring Center is: | a | MedDRA  |
|    |  | b | WHO -ART  |
|    |  | c | VigiFlow  |
|    |  | d | Drug Dossier  |
| 15 | WHO-ART has  | a | 4 levels hierarchical structure   |
|    |  | b | 10 levels hierarchical structure  |
|    |  | c | 5 levels hierarchical structure   |
|    |  | d | 6 levels hierarchical structure   |
| 16 | ICH Guideline E-6 is associated with:  | a | Good Clinical Practice  |
|    |  | b | Pre-clinical Drug Development   |
|    |  | c | Safety Pharmacology Studies   |
|    |  | d | Good Laboratory Practice  |
| 17 | A Blind Subject means:   | a | The subjects do not know which study treatment they receive                                       |
|    |  | b | Patients injected with placebo and active doses   |
|    |  | c | Fake treatment  |
|    |  | d | Signed document of the recruited patient for the clinical trial procedures                        |
| 18 | Pharmaco-epidemiology is defined as:   | a | The Science of Detection, Reporting and Assessment of Adverse Drug Events                         |
|    |  | b | Post Marketing Surveillance   |

|    |  |   |   |
|----|--|---|---|
|    |  | c | Study of Uses and Effects of Drugs in well-defined Population     |
|    |  | d | A compilation of the Clinical Data of the Investigational Product |
| 19 | Pharmacovigilance is done for monitoring of.....     | a | Drug Safety   |
|    |  | b | Drug Price Control  |
|    |  | c | Animal Experiments  |
|    |  | d | Toxicokinetic Studies   |
| 20 | Naranjo scale method of causality assessment is..... | a | Probabilistic method  |
|    |  | b | Algorithmic method  |
|    |  | c | Global introspection.   |
|    |  | d | Dose dependent  |

**Q 2. Attempt ANY ONE Question.**

**12 M**

1. Define and classify ADR, Explain Management of ADR.
2. Write a detailed note on concepts and applications of Pharmacoeconomics & Pharmacoepidemiology

**Q 3. Attempt ANY FOUR Questions.**

**48 M**

1. Describe the Structure and Content of Investigator's Brochure.
2. Give detailed account on Various Active and Passive Surveillance Methods used in Pharmacovigilance.
3. Elaborate on: WHO International Drug Monitoring Programme.
4. Give a detailed account on Good Clinical Practice (ICH-GCP) guidelines.
5. Define the terms: Sponsor and Investigator. Give a detailed account on the Responsibilities of the Sponsor.